Blockchain Registration Transaction Record

VERAXA Biotech Advances Bispecific ADC Program with OmniAb

VERAXA Biotech advances bispecific ADC program VXA-222 with OmniAb, using AND-gate technology to target solid tumors. Learn how this collaboration aims to improve precision cancer therapy.

This news matters because it represents a step forward in precision oncology. The 'AND-gate' approach of VXA-222 could reduce off-target effects and improve outcomes for patients with solid tumors, addressing a significant unmet need. The collaboration between VERAXA and OmniAb exemplifies how combining complementary technologies can accelerate the development of more effective cancer therapies, potentially leading to new treatment options and improved quality of life for patients.